Levofloxacin Hydrochloride Injection

This product belongs to the quinolone antibacterial drug. It is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase and the replication of bacterial DNA. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, and some Escherichia coli. It also has good antibacterial effects on some Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia, etc.

The main ingredients and chemical names of this product are: Levofloxacin hydrochloride, (-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3,-de]-[1,4]benzoxazine-6-carboxylic acid hydrochloride monohydrate. [Molecular formula] C18H20FN3O4·HCl·H2O [Molecular weight] 415.85

This product is light yellow-green or yellow-green clear liquid.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: (1) Respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); (2) Urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; (3) Reproductive system infections: acute prostatitis, acute epididymitis, intrauterine infection, adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); (4 ) Skin and soft tissue infections: infectious impetigo, cellulitis, lymphangitis (adenitis), subcutaneous abscess, perianal abscess, etc.; (5) Intestinal infections: bacterial dysentery, infectious enteritis, Salmonella enteritis, typhoid and paratyphoid; (6) Various infections in patients with sepsis, neutropenia and immunodeficiency; (7) Other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (use metronidazole when necessary), cholecystitis, cholangitis, bone and joint infections, and ENT infections, etc.

Intravenous drip. Adults take 0.4g (4 vials) daily, divided into 2 intravenous drips. 0.2 (2 vials) each time is diluted in 250-500ml of 5% glucose injection or sodium chloride injection. For patients with severe infections and pathogens with poor sensitivity to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 0.6g (6 vials), divided into 2 intravenous drips. 0.3g (3 vials) each time is diluted in 500ml of 5% glucose injection or sodium chloride injection. The drip time for 250ml should not be less than 2 hours, and for 500ml should not be less than 3 hours. [Overdose] In case of overdose, the patient's gastric contents should be cleared, appropriate fluid replacement should be maintained, and clinical observation should be performed.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, abdominal distension, insomnia, dizziness, headache and other neurological symptoms and rash and itching may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 5%. Occasionally, increased blood urea nitrogen, fatigue, fever, palpitations, abnormal taste, etc. are seen. Generally, they are well tolerated and disappear quickly after the end of the course of treatment.

It is contraindicated for those who are allergic to quinolones. [Use in pregnant and lactating women] It is contraindicated for pregnant and lactating women. [Use in children] It is contraindicated for patients under 18 years old. [Overdose] In case of overdose, the patient's stomach contents should be cleared, adequate fluid replacement should be maintained, and clinical observation should be performed. Levofloxacin cannot be effectively eliminated by hemodialysis or peritoneal dialysis.

Precautions for children: Not for use in patients under 18 years of age. Precautions for pregnancy and lactation: Not for use in pregnant or lactating women.

(1) Avoid using it with theophylline. If it is necessary to use it at the same time, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. (2) When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. (3) When used simultaneously with non-steroidal anti-inflammatory drugs, it may cause convulsions. (4) When used simultaneously with oral hypoglycemic drugs, it may cause blood sugar disorders, including hyperglycemia and hypoglycemia. Therefore, blood sugar concentrations should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given. (5) When this product is used simultaneously with drugs such as antacids containing magnesium or aluminum, sucralfate, metal cations (such as iron), and multivitamin preparations containing zinc, it will interfere with the gastrointestinal absorption of this product, causing the concentration of this drug in various systems to be significantly reduced. Therefore, the time of taking the above drugs should be at least 2 hours before or after taking this product.

Keep in a dark, cool and dry place. [Validity period] 1.5 years